New immuno-oncology personalized therapy approaches

Genome & Company is developing a microbiome-based add-on therapy for programmed cell death 1/programmed cell death1 ligand1 inhibitors. It is also developing novel targeted immune checkpoint inhibitors, and believes these two approaches could be combined for personalized therapy.


Genome & Company’s lead development program, GEN-001, is a microbiome-based therapy. There is growing evidence that modulating the gut microbiome could improve therapeutic responses to cancer immunotherapy. “We believe our microbiome asset could improve the response rate and efficacy if used as an add-on therapy with existing anti-PD-1/PD-L1 [programmed cell death1/programmed cell death1 ligand1] drugs,” said Kyoung Wan Yoon, CSO at Genome & Company.

기사 전문보기

No comments

    댓글은 닫혔습니다.